Biotechnology company Mesoblast (NASDAQ: MESO) shares are plummeting premarket after the company said that its COVID-19 treatment was unlikely to meet its primary endpoint.
Mesoblast shares are down 31.83% on Friday at $9.25 following Thursday’s close at $13.57. Its Australian-listed stock price fell 36.07% to A$2.41 after the news.
In a press release, the company said that the trial was aiming to achieve a primary endpoint of a 43% reduction in mortality at 30 days for treatment with remestemcel-L on top of maximal care in a trial of 300 patients with the mortality reduction target based on pilot data observed during the initial stages of the pandemic.
Ready to put what you’ve learned into practice?
Try IG’s platform with £10,000 in virtual funds and practise trading
without putting your own money at risk.
Try IG with a demo account →
Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 69% of retail investor accounts lose money when trading spread bets and CFDs with this provider.
Learn the markets with IG Academy
Build your knowledge with IG Academy educational content, then use a
demo account to practise what you’ve learned on the IG platform.
Explore IG →
Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 69% of retail investor accounts lose money when trading spread bets and CFDs with this provider.
See how trading works before risking real money
IG’s demo gives you access to thousands of markets and £10,000 in
virtual funds, so you can explore the platform and test your ideas first.
Open an IG demo →
Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 69% of retail investor accounts lose money when trading spread bets and CFDs with this provider.
Turn trading theory into practical experience
Learn with IG Academy, explore charts and market tools, and practise
strategies in a simulated trading environment before going live.
Start practising with IG →
Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 69% of retail investor accounts lose money when trading spread bets and CFDs with this provider.
Ready to take your learning further?
IG combines market education, analysis and an established trading platform,
giving you the tools to keep learning as you develop your trading skills.
Discover IG →
Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 69% of retail investor accounts lose money when trading spread bets and CFDs with this provider.
However, the Data Safety Monitoring Board (DSMB) reported that while there were no safety concerns, the trial is not likely to meet its primary endpoint.
The trial has not yet accrued data on the secondary endpoints, and the company will still carry out the study using the 223 patients that are already enrolled.
